Company Overview

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

  • Name

    Illumina, Inc.

  • CEO

    Mr. Jacob Thaysen Ph.D.

  • Website

    www.illumina.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1998

Profile

  • Market Cap

    $21.41B

  • EV

    $23.34B

  • Shares Out

    159.3M

  • Revenue

    $4,429M

  • Employees

    10,615

Margins

  • Gross

    66.34%

  • EBITDA

    14.34%

  • Operating

    4.63%

  • Pre-Tax

    -68.55%

  • Net

    -68.73%

  • FCF

    8.06%

Returns (5Yr Avg)

  • ROA

    -4.4%

  • ROTA

    -18.21%

  • ROE

    -8.05%

  • ROCE

    6.49%

  • ROIC

    7.79%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $149.23

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $994M

  • Net Debt

    $1,927M

  • Debt/Equity

    2.03

  • EBIT/Interest

    2.66

Growth (CAGR)

  • Rev 3Yr

    3.75%

  • Rev 5Yr

    5.4%

  • Rev 10Yr

    10.63%

  • Dil EPS 3Yr

    54.35%

  • Dil EPS 5Yr

    24.98%

  • Dil EPS 10Yr

    29.07%

  • Rev Fwd 2Yr

    0.69%

  • EBITDA Fwd 2Yr

    60.88%

  • EPS Fwd 2Yr

    127.76%

  • EPS LT Growth Est

    33.81%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

NasdaqGS:ILMN